Skip to main content

Table 4 Tumor response per RECIST v1.1

From: A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

  25 mg (n = 1) 50 mg (n = 3) 75 mg (n = 3) 100 mg (n = 10) 125 mg (n = 10) 150 mg (n = 10) 175 mg (n = 3) All patients (n = 40)
Best overall response, n (%)
 Complete response 0 0 0 0 0 0 0 0
 Partial response 0 0 0 0 1 (10.0) 1 (10.0) 0 2 (5.0)
 Stable disease 0 2 (66.7) 1 (33.3) 7 (70.0) 4 (40.0) 7 (70.0) 2 (66.7) 23 (57.5)
 Progressive disease 1 1 (33.3) 2 (66.7) 3 (30.0) 5 (50.0) 2 (20.0) 1 (33.3) 15 (37.5)
 DCR, % (95% CI) 0 (NR) 66.7 (9.4–99.2) 33.3 (0.8–90.6) 70.0 (34.8–93.3) 50.0 (18.7–81.3) 80.0 (44.4–97.5) 66.7 (9.4–99.2) 62.5 (45.8–77.3)
  1. DCR disease control rate, NR not reached, RECIST response evaluation criteria in solid tumors